In Arm 2A of the trial, patients with RT (n=42) received epcoritamab monotherapy in the first-line setting or in second- or later-line settings, with a median follow-up of 22.9 months. In the ...
Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the ...
As they say, life doesn’t stop at 40. Turning 40 doesn't mean giving up on strength or dreaming of a toned, strong body; rather, it means training smarter with purpose and methods backed by science ...
On top of strength training, I’ve upped my daily step count to 12,000 steps a day and regularly incorporate short cardio ...
In the session 'Catalysts of Transformation,' MPW 2025 presents a candid, insightful conversation moderated by Siddharth Zarabi, featuring women who helm some of India's most respected legacy and next ...
Combining CIT with BTKi may enhance complete response rates and progression-free survival in RT-DLBCL compared to CIT alone. The study observed no statistically significant difference in overall ...
Stefanie van Hooijdonk has come a long way in HR — both professionally and geographically. She says she got her start as a junior HR consultant in the Netherlands, her native country, before starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback